Travere Therapeutics

ISIN US89422G1076

 | 

WKN A2QHYP

Market cap (in EUR)
2,674 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.
Show more Show less
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States

Financials

Key metrics

Market capitalisation, EUR 2,674 m
EPS, EUR -0.98
P/B ratio 42.4
P/E ratio -
Dividend yield 0.00%

Income statement (2024)

Revenue, EUR 216 m
Net income, EUR -296 m
Profit margin -137.51%

What ETF is Travere Therapeutics in?

There are 4 ETFs which contain Travere Therapeutics. All of these ETFs are listed in the table below. The ETF with the largest weighting of Travere Therapeutics is the L&G Pharma Breakthrough UCITS ETF.
ETF Weight Investment focus Fund size (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.23%
Equity
United States
Health Care
Biotech
44
L&G Russell 2000 US Small Cap Quality UCITS ETF 0.05%
Equity
United States
Small Cap
172
L&G Pharma Breakthrough UCITS ETF 2.98%
Equity
World
Health Care
Innovation
16
JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist) 0.05%
Equity
United States
Small Cap
176
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.